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Abstract
A widespread decrease of mature microRNAs is often observed in human malignancies giving them potential
to act as tumor suppressors. Thus, microRNAs may be potential targets for cancer therapy. The global miRNA
deregulation is often the result of defects in the miRNA biogenesis pathway, such as genomic mutation or aberrant
expression/localization of enzymes and cofactors responsible of miRNA maturation. Alterations in the miRNA
biogenesis machinery impact on the establishment and development of cancer programs. Accumulation of
pri-microRNAs and corresponding depletion of mature microRNAs occurs in human cancers compared to normal
tissues, strongly indicating an impairment of crucial steps in microRNA biogenesis. In agreement, inhibition of
microRNA biogenesis, by depletion of Dicer1 and Drosha, tends to enhance tumorigenesis in vivo. The p53 tumor
suppressor gene, TP53, is mutated in half of human tumors resulting in an oncogene with Gain-Of-Function
activities. In this review we discuss recent studies that have underlined a role of mutant p53 (mutp53) on the
global regulation of miRNA biogenesis in cancer. In particular we describe how a new transcriptionally independent
function of mutant p53 in miRNA maturation, through a mechanism by which this oncogene is able to interfere
with the Drosha processing machinery, generally inhibits miRNA processing in cancer and consequently impacts
on carcinogenesis.
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Background
MicroRNAs (miRNAs) are small non coding single-
stranded RNAs of about 20–25 nucleotides in length that
regulate gene expression by binding to complementary
target mRNAs and promoting their decay or inhibit-
ing their translation [1–3]. 1881 human mirRNA loci,
annotated on miRBase21, and an even greater number
of predicted miRNA targets have been identified in the hu-
man genome. Thus, miRNAs are potent regulators of gene
expression involved in diverse physiological processes, such
as normal development, differentiation, growth control,
apoptosis, and in human diseases, particularly in cancer
where they act as regulators of key cancer-related pathways
[4–6]. The expression level of biologically active mature
miRNAs is the result of a fine mechanism of biogenesis,
carried out by different enzymatic complexes that exert
their function at transcriptional and post-transcriptional
levels. MiRNAs sequences are distributed all throughout
the genome, being localized in exonic or intronic regions,
as well as intergenic locations [7]. The biogenesis of miR-
NAs starts with their transcription by RNA polymerase II,
[8] although some other miRNAs are transcribed by RNA
polymerase III, [9] resulting in a primary transcript known
as pri-miRNA which have a stem-loop structure, are
capped at the 5′-end and have a 3′-poly (A) tail. The
canonical miRNA biogenesis pathway is characterized by
two subsequent central steps utilizing ribonuclease reac-
tions (Fig. 1). In the nucleus, pri-miRNAs are recognized
and cropped into hairpin-structured precursor miRNAs
(pre-miRNAs) by the Drosha complex (also known as
Microprocessor complex). Drosha, an RNase III enzyme,
and DGCR8 (DiGeorge critical region 8), a double-
stranded RNA-binding domain (dsRBD) protein, are two
essential components of the Microprocessor complex.
Drosha liberates the stem_loop pre-miRNAs from pri-
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miRNAs in cooperation with DGCR8-mediated recogni-
tion of the junctional region between the single-stranded
and double-stranded portions of pri-miRNAs [10, 11]. The
Drosha complex also contains several auxiliary factors in-
cluding the DEAD-box RNA helicases p68 (DDX5) and
p72/p82 (DDX17) which promote the fidelity and activity
of Drosha processing [12]. The pre-miRNAs of approxi-
mately 70 nucleotides in length are transported from the
nucleus to the cytoplasm by Exportin-5 (XPO5) together








































Fig. 1 Schematic representation of canonical miRNA biogenesis pathway. The miRNA biogenesis is a multistep process. miRNA genes are transcribed
by polymerase II or III resulting in primary precursors (pri-miRNAs). Second, pri-miRNAs are cleaved into pre-miRNA by the Microprocessor complex
(Drosha-DGCR8) in the nucleus and then transported from the nucleus to the cytoplasm by Exportin-5-Ran-GTP. Drosha/DGCR8 is subjected to
complex regulation by positive and negative factors, represented on the figure. In the cytoplasm, Dicer1, TRBP and Paz protein cleave and digest the
pre-miRNA to produce a mature duplex miRNA. The functional strand of the mature miRNA is loaded together with AGO-2 proteins into the RISC.
The mature miRNA silences target mRNAs through mRNA cleavage or translational repression
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RNase III, digests the pre-miRNA into a 20–25 nucleotides
mature duplex miRNA. During this process, Dicer is
associated with other proteins like TAR RNA binding
protein (TRBP) and kinase R–activating protein (PACT) to
increase its stability and its processing activity [14, 15]. The
miRNA duplex is comprised of two miRNA strands, with
one strand loaded onto the RNA-induced silencing com-
plex (RISC), which contains the Argonaute (Ago) family
protein as a core component. In these processes, the other
strand (miRNA* strand) is usually degraded, however, in
some cases miRNA* strands are retained and function
[16]. Mature miRNAs serve as guides directing RISC to
target mRNAs, which are degraded, destabilized or transla-
tionally inhibited by the Ago proteins [17].
Deregulation of miRNAs is commonly observed in
human cancers [17]. Microarray expression data from a
wide spectrum of cancer diseases have evidenced a
general aberrant miRNA expression in cancer [18–20]
and a large amount of data have revealed that the
physiological state of cancer cells can be detected by
miRNA expression profiling [21, 22]. Importantly, single
miRNA may target up to several hundred mRNAs,
indeed an aberrant miRNA expression may profoundly
influence cancer-related signaling pathways. In agree-
ment, mouse models displaying miRNA overexpression
or depletion have demonstrated causal links between
miRNAs and cancer development making them putative
therapeutic targets [22, 23]. Although miRNAs can func-
tion as both tumour suppressors and oncogenes in tumour
development, a widespread down-regulation of miRNAs is
commonly observed in human cancers [5, 17, 24, 25],
suggesting that miRNAs are primarily tumor suppressor
genes. The global down-regulation in miRNA expression
arises through multiple mechanisms: genetic alterations
[26–28], transcriptional regulation (epigenetic mecha-
nisms, miRNA suppression by oncogenic transcription fac-
tors, miRNA downregulation by loss of tumour suppressor
transcription factors) and post-transcriptional regulation
[29, 30]. An increasing number of evidences indicate that
post-transcriptional maturation, rather than transcrip-
tion, is often perturbed in cancer. The accumulation
of pri-miRNAs and the corresponding depletion of
mature miRNAs have been evidenced in human cancers
compared to normal tissue [31], strongly indicating that
the impairment of crucial steps in miRNA biogenesis
could be the underlying cause.
Recent studies have identified that deregulated expres-
sion and subcellular localization of Drosha, Dicer and
TARBP1 correlate with disease progression and poor
prognosis in different types of tumors [30]. Moreover,
genetic defects in genes encoding Dicer1 [32], exportin5
[33] and TARBP2 [34] have been found underscoring
the relevance of the processing machinery of miRNA in
cancer. Recently two studies showed that mutations in
the SIX1/2 pathway and the DROSHA/DGCR8 miRNA
Microprocessor complex underlie high-risk blastemal
type Wilms tumors [35, 36]. Finally the repression of
miRNA processing by the partial depletion of Dicer1
and Drosha accelerates cellular transformation and
tumorigenesis in vivo [37].
The biogenesis of miRNAs requires not only the core
processing enzymatic machinery, but also many regula-
tory factors, such as RNA binding factor or transcription
factors often deregulated in cancer cells. A panel of
modulators that have been reported to influence the pro-
cessing of pri-miRNAs including p68 (DDX5), p72/p82
(DDX17), DDX1, BRCA, ARS2, DR5, ADAR1, hRNP A1,
KSRP, Lin 28, SMADs, YAP, ERα, ERβ, wtp53 and mutant
p53 [38–58] (Fig. 1), imply that there is a link between
oncogene and oncosuppressors pathways and the Micro-
processor complex.
p68 (DDX5) and p72/p82 (DDX17) are prototypic
members of the DEAD box protein family of RNA heli-
cases. Both p68 and p72 are responsible for the process-
ing of a subset of pri-miRNAs [38, 59] and acting as a
bridge between Drosha and other proteins can impact
on cancer development by regulating known oncogenes
and tumor suppressors. Indeed, several molecules,
involved in different signalling pathways, have been
described to bind p68 and/or p72/82 regulating Drosha/
DGCR8 mediated miRNAs processing such as wtp53
and mutp53 [52, 56, 57].
The TP53 tumour suppressor is one of the most
important and well-studied cancer gene, and it is not
surprising that it has been found to have a role in
miRNA regulation. More than 50 % of human cancers
carry mutations within the p53 locus [60]. The common
types of cancer–associated p53 mutations are missense
mutations mainly located in the DNA binding domain of
p53. The resulting full-length mutant p53 protein is
unable to activate transcription of wtp53 target genes
connected with cell cycle arrest, apoptosis and DNA
repair [61–63]. Furthermore, mutant p53 (mutp53)
proteins can acquire novel oncogenic functions known
as gain of function activities (GOF) favouring in vivo
tumor induction, maintenance and spreading in mouse
models [64]. At molecular level, GOF mutant p53 pro-
teins can exert their activities either through the binding,
the sequestration, and the inactivation of tumor suppres-
sor proteins or through the transcriptional regulation of
target genes [65, 66]. The widespread nature of p53 mu-
tations in cancer has suggested a relationship between
mutp53 GOF activities and the deregulation of miRNA
biogenesis observed in cancer. Indeed, the understanding
of these mechanisms is a cardinal question in cancer
biology. Some very recent experimental efforts have
provided substantial advances in understanding miRNA
biogenesis and its regulation by p53 proteins. These
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findings will impact on the knowledge of the molecular
mechanisms through which mutp53s exert their GOF
activities, and regulate gene expression, by adding to this
puzzle the ability to interfere with miRNA processing.
Wtp53-Microprocessor complex interplay
The first evidence of a direct involvement of wtp53 on
miRNA biogenesis has been described by Suzuki and
collaborators in 2009 [52]. They found that in colon
carcinoma cell line HCT116, after DNA damage (Doxoru-
bicine), wtp53 interacts with the Drosha complex through
its DNA binding domain, facilitating the processing of a
subset of nine pri-miRNAs including pri-miR-16-1, −143,
−145 and −206, with growth suppressive function. They
found that wtp53 expression induced an increase in the
p68 association to Drosha–complex that in turn increases
Drosha activity. Moreover, their data strongly indicate that
p53 interacts with the Drosha complex through RNA mol-
ecules and p68. The authors also demonstrated that sev-
eral of the wtp53-regulated miRNAs decrease cell
proliferation rate targeting k-Ras (miR-143), and CDK6
(miR-16, 26a, −107, −145, −206). These results underlie a
novel function of wtp53 in miRNA maturation and
strongly indicate a role for wtp53 controlling global gene
expression and cell fate by positively modulating Micro-
processor activity. Subsequently three different groups
have described a role of the wtp53 on pri-miRNA process-
ing. In a recent work Kazuya Nakazawa and colleagues
provide evidences regarding the role of an activated p53
on pri-miR-1915 processing in response to DNA damage
(Adriamicine) [53]. J Chang and colleagues found that
after HCT116 cells treatment with the DNA damaging
agent camptotecina (CPT), that induces wtp53 accumula-
tion and consequently apoptosis, wtp53 leads to the
expression of 5 miRNAs (miR-16, −103, −143, −203, 206)
at post-transcriptional level [54]. Of note the authors
found a mechanism by which the acetylation of K120 in
the DNA-binding domain of wtp53, which play a critical
role in mediating apoptosis, augments its association with
the Drosha Microprocessor complex and the interaction
between Drosha and p68. In agreement, the knockdown
of hMOF, the acetyltransferase that targets K120 in p53,
strongly reduces miRNA induction and apoptosis medi-
ated by CPT. Finally the authors found that downregula-
tion of anti-apoptotic Bcl-w by miR-203 is necessary for
cell death upon CPT treatment indicating that post-
transcriptional regulation of gene expression by wtp53 via
miRNAs plays a role in determining stress-specific cellular
outcomes. Moreover, altogether these findings strongly
suggest that the mutated p53K120R found in tumors may
contribute to tumorigenesis and to resistance to chemo-
therapy also through deregulation of miRNA biosynthesis.
Of interest, other post translational modifications that are
induced after DNA damage and play a key role on cellular
response, globally induce miRNA biogenesis. Indeed,
after DNA damage, ATM kinase directly binds to and
phosphorylates KSRP, leading to enhanced interaction
between KSRP and pri-miRNAs increasing miRNA
processing by Drosha [67]. Two papers underline a
SIRT1-wtp53-miR34a axis. Herbert KT et al. have
described that SIRT1 modulates wtp53 acetylation
statusthus promoting maturation of pri-miRNAs
transcripts, among which miR-34a [55].
A SIRT1-wtp53-miR34a axis has been also described
in which SIRT1, de-acetylating wtp53 (K382), inhibits
Table 1 MiRNAs regulated by mutant p53
miRNA References Biological functions References
Transcriptionally regulated
27a 75 Cell growth, tumorigenesis 75
let7i 76 Inhibition of cell invasion and
migration
76
130b 77 EMT repression 77
155 78 Cell invasion, metastasis 78
128-2 79 Anti-apoptotic, chemoresistance 79
223 80 Pro-apoptotic 80
520 g 57 Chemoresistance 81
518b 57 Inhibition of cell proliferation and
invasion
82
582 57 Inhibition of cell proliferation and
invasion
83
141 57 EMT repression 84
519c 57 Inhibition of angiogenesis 85
143 57 cell cycle arrest, apoptosis 86, 87




26a 56 Repression of EMT and invasion 56
16 52 Inhibition of cell growth and
angiogenesis
52
206 52 Inhibition of cell growth and
angiogenesis
93
18a 58 Cell proliferation, invasion,
tumorigenesis
58
517a 57 Inhibition of proliferation, apoptosis 57, 89
218 57 Inhibition of EMT and invasion 57, 90
519a 57 Inhibition of proliferation, migration
and EMT
57, 91
105 57 Inhibition of proliferation 57
628 57 Unknown
515 57 Inhibition of proliferation, apoptosis 92
1 57 Suppression of cell growth, invasion,
metastasis
93
The table lists miRNAs regulated by mutp53 both at transcriptional and
post-transcriptional level. Biological functions of miRNAs and references are
mentioned (on the left references relatives to the mut p53-dependent
regulation, on the right those referred to their biological role)
Gurtner et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:45 Page 4 of 9
pri-miR-34a maturation in normal keratinocytes.
Interestingly, this SIRT1 dependent regulation of
miRNA biogenesis seems to be impaired on keratino-
cyte cell line with p53 mutations. Nevertheless, by the
experiments described on the manuscript it is not
clear which step of miRNA biogenesis is governed by
wtp53-SIRT cross-talk [68]. Interestingly, wtp53 in-
duces a RNA-binding protein, RBM38, that blocks
miRNAs accessibility to 3′UTR of several wtp53 tar-
get genes that promote cell death upon genotoxic
stress, such as the 3′UTR of p21- [69]. Notably the
accessibility of the 3′UTR of SIRT1, that is targeted
by miR-34a promoting cell survival, is not under
RBM38 regulation.
Impact of mutp53 on miRNA biogenesis
In 2009, in the same manuscript concerning the role
of wtp53 in miRNA processing, Suzuki and collabora-
tors provide evidences that the overexpression of
three tumor GOF-p53 mutants in the DNA binding do-
main (R273H, R175H, C135Y) in colon carcinoma HCT
p53-null cell line, decreases the ability of an ectopic
expressed Drosha to bind p68 and pri-miRNAs, leading to
inhibition of processing of three wtp53-dependent-
miRNAs [52]. The last was the first experimental data
suggesting the idea that a novel oncogenic property of
mutp53 is the attenuation of miRNA post-transcriptional
maturation.
Later, in the 2015, Jiang FZ et al. found that the over-
expression of different mutp53 proteins (C135Y, R175H,
R248Q, R273H) in p53-null endometrial carcinoma cell
lines (HEC-50) disrupts p68-Drosha complex assembly
and inhibits the recruitment of Drosha on pri-miRNA-
26a1 [56], confirming in part the results obtained by
Suzuki on colon cancer cells [52]. Interestingly, the
authors demonstrated that in HEC-1B cells, endogen-
ously expressing mutantp53-R248Q, the last binds p68
suggesting that it titrates this RNA helicase from the
Microprocessor complex. In these cells, mutp53 pro-
motes the epithelial to mesenchymal transition by
repressing miR-26a expression that in turn inhibits
EZH2 (the transcriptional repressor Enhancer of Zeste
Homolog2), both in vitro and in xenograft experiments
[56]. EZH2 is an oncogene upregulated in several tumors
that epigenetically silences a plethora of oncosuppressor
genes [70]. Thus, due to the widespread activity of EZH2
on gene expression regulation, the biological effects of
mutant p53-dependent regulation of miRNAs that
modulate this oncogene, would profoundly impact on
cell cancer biology.
Very recently, we have demonstrated that the
endogenous GOF-mutp53 proteins modulate the bio-
genesis of several miRNAs in cancer cells directly
interfering with Drosha-p72 association and promot-
ing cell survival and cell migration [57]. By a genome
wide analysis of miRNA expression on colon cancer
cell line SW480, we observed that, upon endogenous
mutp53-R273H depletion, frequently present in
human tumors, 33 out of 376 miRNAs analyzed were




















Fig. 2 Representation of molecular mechanisms through which wtp53 (green) and mutp53 (red) impact on Drosha activity. Upon DNA damage,
the complex p53/p68 binds the microprocessor complex fostering the maturation of a subset of pri-miRNAs to pre-miRNAs. In a cellular context
in which mutp53 is expressed, the last binds p68 and p72, the Microprocessor complex is dissociated and the maturation of a subset of pri-miRNAs to
pre-miRNAs is impaired
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indicating, for the first time, that mutp53 may be
responsible at least in part for the miRNAs downregula-
tion observed in cancer. Moreover, we found that another
missense mutp53-R175H, inhibits the expression of
several of these miRNAs in breast cancer cells (SKBR3).
This strongly points out a general mechanism that
involves different p53 proteins with missense muta-
tions and suggests that the signature of miRNAs
downregulated by mutp53 proteins in different solid
tumors has, at least in part, common members. From
a mechanistic point of view, through pri- pre- and
mature form analysis, we found that mutp53 downre-
gulates miRNAs not only at transcriptional but also
at post-transcriptional level. In agreement, we dem-
onstrated that endogenous mutp53 proteins (R273H
and R175H) directly bind p72/82 through its N-
terminal domain, hindering the association of this
DEAD-box with the Microprocessor complex and pri-
miRNAs, and leading to the inhibition of the biogen-
esis of a subset of miRNAs positively regulated by
p72. Of note we found that the endogenous wtp53
has an opposite effect on the expression of mutp53
repressed miRNAs on colon cancer cell lines con-
firming the contribution of mutant p53 GOF on
miRNA repression.
On the other hand, in 2014, Li and colleagues, as
well, have provided evidences that mutp53 can pro-
mote microRNA biogenesis [58]. The authors demon-
strate that different mutp53 regulate the amount of
ERα protein by regulating the biogenesis of miR-18a,
which in turn decreases the tumor-protective func-
tion of the estrogen pathway in female hepatocarcino-
genesis [58, 71]. Although the authors don’t describe
in detail the molecular mechanism, they provided
some evidences of the impairment of pri-miRNA pro-
cessing driving by mutp53, in cells and in human
hepatocellular carcinoma (HCC) samples. They found
that the precursor and mature form of miRNA-18a,
but not the primary transcript, are upregulated in
liver tissues collected from 77 female HCC patients.
They identify mutp53 as a putative factor involved in
the regulation of the processing of miR-18a, but not
of the other member of the oncogenic cluster miR-
17 ∼ 92 [72–74]. Moreover, the overexpression of
several p53 proteins mutated in the DNA binding
domain (K132E, I162F, I232F, R249S), frequently
observed in HCC, greatly increase the level of miR-
18a and decrease, though at different extent, the levels
of its primary transcript. To summarize the data available
up today, in Table 1 is shown a list of miRNAs that have
been demonstrated to be regulated by mutp53 both a
transcriptional and posttranscriptional level. In the
same table are also indicated the available data about
the biological function of these miRNAs (75-93).
Conclusions
Collectively in the last five years, several experimental
evidences in different cellular contexts have demon-
strated that several GOF-mutp53 regulate miRNA
biogenesis by acting on Drosha complex activity.
Based on the evidences available so far, two molecular
mechanisms underlying the mutp53-dependent modula-
tion of miRNA processing can be proposed: 1) wtp53
increases pri-miRNA biogenesis by a direct binding with
Drosha and p68 cofactors, while, on the contrary,
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Fig. 3 pri-miRNA regulation by mutp53 proteins and functions. In
the figure the three published papers providing demonstrations of
the impact of mutp53 isoforms on Microprocessor complex are
highlighted. The miRNAs described in the papers and the functional
consequences of their downregulation are also indicated
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by sequestering p68; 2) mutp53 directly binds p72/82
and represses Drosha activity (Fig. 2). By a functional
point of view, these two molecular mechanisms lead to
an increase of cell migration, epithelial to mesenchymal
transition and cell survival (Fig. 3).
p68 and p72/82, as co-factor of the Microprocessor
complex, are involved in the Drosha miRNA processing
of several but not all miRNAs. Masaki Mori and collabo-
rators [49] have provided some findings suggesting that
p72 selectively binds a VCAUCH sequence motif present
in the 3′ of some pri-miRNAs to enhance the Drosha
processing. Although, the precise role of these two RNA
helicases in pri-miRNA processing is unknown. Further
biochemical and bioinformatics experiments are needed
to better identify the sequence motif and structures
of pri-miRNAs that are selectively regulated by the
mutp53/p72/Drosha and mutp53/p68/Drosha axis.
Since mutations in TP53 occur at high frequency in
human cancers, developing strategies to block the
oncogenic effects of mutp53 will be an important
step for their treatment. By this point of view, it is
important to notice that, mutant p53, as well as
wtp53, impact on miRNA biogenesis not only at the
level of Drosha but also regulating miRNA transcrip-
tion as well as maturation from pre- to mature miR-
NAs. Thus, since miRNAs are powerful regulators of
gene expression, the biological effects of miRNAs
downregulation by mutp53 are profound.
It would be interesting in the future to identify, on
a larger scale, the entire repertoire of miRNAs
negatively downregulated by different mutp53 in
different tumor models and in human samples. The
characterization of the entire gene-regulatory net-
works governed by mutp53-miRNA cross-talks will
offer a molecular basis for diagnostic and therapeutic
strategies based on miRNA biology. Indeed, it is
possible to envisage that a specific miRNA signature,
both in human tissues or in biological fluids, such as
plasma, could be useful to predict mutant p53 status.
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